ADARx Pharmaceuticals seeks $1.74 billion valuation in US IPO
ADARx Pharmaceuticals is reportedly targeting a valuation of $1.74 billion in its upcoming U.S. initial public offering. This information, indicating the drug developer's aim, has been reported by both Investing.com and Reuters. The valuation is a target set by the company, not a finalized market value.
2 articles from 2 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
2 outlets covered “ADARx Pharmaceuticals seeks $1.74 billion valuation in US IPO”. All of them report the following:
- ADARx Pharmaceuticals
- targets $1.74 billion valuation
- US IPO
- drug developer
Which outlets covered this?
All 2 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.
pragmatist2